832
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Relationship between Antithrombin III Activity and Mortality in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

, , , , , & show all
Pages 353-364 | Received 26 Jan 2022, Accepted 22 Jul 2022, Published online: 05 Dec 2022

References

  • López-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23. Epub 2015/10/24. DOI:10.1111/resp.12660
  • Løkke A, Hilberg O, Tønnesen P, et al. Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998–2010. BMJ Open. 2014;2014/;4(1):e004069. Epub 01/08. DOI:10.1136/bmjopen-2013-004069 PubMed PMID: 24394800; PubMed Central PMCID: PMCPMC3902350.
  • Liu M, Hu R, Jiang X, et al. Coagulation dysfunction in patients with AECOPD and its relation to infection and hypercapnia. J Clin Lab Anal. 2021;35(4):e23733. Epub 2021/03/26. DOI:10.1002/jcla.23733 PubMed PMID: 33764623; PubMed Central PMCID: PMCPMC8059715.
  • DAHL M, TYBJOERG-HANSEN ANNE, VESTBO J, et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(6):1008–1011. Epub 2001/10/06. doi:10.1164/ajrccm.164.6.2010067.
  • Duvoix A, Dickens J, Haq I, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2013;68(7):670–676. Epub 2012/06/30. DOI:10.1136/thoraxjnl-2012-201871 PubMed PMID: 22744884; PubMed Central PMCID: PMCPMC3711372.
  • Serban KA, Pratte KA, Bowler RP. Protein biomarkers for COPD outcomes. Chest. 2021;159(6):2244–2253. Epub 2021/01/13. DOI:10.1016/j.chest.2021.01.004 PubMed PMID: 33434499; PubMed Central PMCID: PMCPMC8213963.
  • Husebø GR, Gabazza EC, D’Alessandro Gabazza C, et al. Coagulation markers as predictors for clinical events in COPD. Respirology. 2021;26(4):342–351. Epub 2020/11/10. DOI:10.1111/resp.13971
  • Fruchter O, Yigla M, Kramer MR. D-dimer as a prognostic biomarker for mortality in chronic obstructive pulmonary disease exacerbation. Am J Med Sci. 2015;349(1):29–35. Epub 2014/09/19. DOI:10.1097/maj.0000000000000332
  • Vaidyula VR, Criner GJ, Grabianowski C, et al. Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease. Thrombosis Research. 2009;124(3):259–261. Epub 2009/01/24. PubMed PMID: 19162305; PubMed Central PMCID: PMCPMC2877030. DOI:10.1016/j.thromres.2008.12.030
  • Kunter E, Ilvan A, Ozmen N, et al. Effect of corticosteroids on hemostasis and pulmonary arterial pressure during chronic obstructive pulmonary disease exacerbation. Respiration. 2008;75(2):145–154. Epub 2006/12/05. DOI:10.1159/000097748
  • Mariĭnov K, Petrova D, Kamenov V, et al. Anticoagulants and changes in the coagulation status of patients with chronic obstructive lung disease and various degrees of respiratory failure. Vutreshni Bolesti. 1988;27(1):86–93. Epub 1988/01/01.
  • Zuo XJ, Nicolaidou E, Okada Y, et al. Antithrombin III inhibits lymphocyte proliferation, immunoglobulin production and mRNA expression of lymphocyte growth factors (IL-2, gamma-IFN and IL-4) in vitro. Transpl Immunol. 2001;9(1):1–6. Epub 2001/10/30. DOI:10.1016/s0966-3274(01)00042-9
  • Umerah CO, Momodu II. Anticoagulation. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC; 2022.
  • Di Stefano A, Turato G, Maestrelli P, et al. Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa. Am J Respir Crit Care Med. 1996;153(2):629–632. Epub 1996/02/01. DOI:10.1164/ajrccm.153.2.8564109
  • Ma Y, Wang J, Gao J, et al. Antithrombin up-regulates AMP-activated protein kinase signalling during myocardial ischaemia/reperfusion injury. Thromb Haemost. 2015;113(2):338–349. Epub 2014/09/19. DOI:10.1160/th14-04-0360 PubMed PMID: 25230600; PubMed Central PMCID: PMCPMC4308562.
  • Aytekin FO, Tekin K, Kabay B, et al. Antithrombin III attenuates pulmonary tissue injury caused by mesenteric ischemia-reperfusion. Am J Surg. 2005;189(2):161–166. Epub 2005/02/22. DOI:10.1016/j.amjsurg.2004.11.003
  • Lu J, Niu D, Zheng D, et al. Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin III for acute coronary syndrome risk. Biom Rep. 2018;9(6):517–522. Epub 2018/12/14. PubMed PMID: 30546880; PubMed Central PMCID: PMCPMC6256189. DOI:10.3892/br.2018.1162
  • Lestari IN, Yoel C, Lubis M. The association between the level of antithrombin III and mortality in children with sepsis. Open Access Maced J Med Sci. 2019;7(6):959–961. Epub 2019/04/13. DOI:10.3889/oamjms.2019.211 PubMed PMID: 30976340; PubMed Central PMCID: PMCPMC6454173.
  • Pettilä V, Pentti J, Pettilä M, et al. Predictive value of antithrombin III and serum C-reactive protein concentration in critically ill patients with suspected sepsis. Crit Care Med. 2002;30(2):271–275. Epub 2002/03/13. DOI:10.1097/00003246-200202000-00001
  • Allingstrup M, Wetterslev J, Ravn FB, et al. Antithrombin III for critically ill patients. Cochrane Database Syst Rev. 2016;2(2):Cd005370. // DOI:10.1002/14651858.CD005370.pub3
  • StatBox: A Online Statistical Computing System. Biostatistics Team of CMT. https://www.biostats.cn/statbox/.
  • GOLD Executive Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Updated 2017). Available from: https://goldcopd.org/.
  • Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–35. Epub 1950/01/01. DOI:10.1002/1097-0142(1950)3:1 < 32::aid-cncr2820030106 > 3.0.co;2-3
  • Wirtz HR. [Chronic bronchitis, COPD]. Internist (Berl). 2005;46(2):175–191. quiz 92-3. Epub 2005/01/19. DOI:10.1007/s00108-004-1335-z
  • Wang Y, Xu J, Meng Y, et al. Role of inflammatory cells in airway remodeling in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3341–3348. Epub 2018/10/24. DOI:10.2147/copd.S176122 PubMed PMID: 30349237; PubMed Central PMCID: PMCPMC6190811.
  • Polosa R, Malerba M, Cacciola RR, et al. Effect of acute exacerbations on circulating endothelial, clotting and fibrinolytic markers in COPD patients. Intern Emerg Med. 2013;8(7):567–574. Epub 2011/06/11. DOI:10.1007/s11739-011-0636-1
  • Sungurlu S, Kuppy J, Balk RA. Role of antithrombin III and tissue factor pathway in the pathogenesis of sepsis. Crit Care Clin. 2020;36(2):255–265. Epub 2020/03/17. DOI:10.1016/j.ccc.2019.12.002
  • Bergantini L, d’Alessandro M, Cameli P, et al. Antithrombin III as predictive indicator of survival in idiopathic pulmonary fibrosis (IPF) patients treated with nintedanib: a preliminary study. Intern Med J. 2021;51(5):705–711. Epub 2020/02/11. DOI:10.1111/imj.14768
  • Rehberg S, Yamamoto Y, Sousse LE, et al. Antithrombin attenuates vascular leakage via inhibiting neutrophil activation in acute lung injury. Crit Care Med. 2013;41(12):e439-46. Epub 2013/10/11. DOI:10.1097/CCM.0b013e318298ad3aPubMed PMID: 24107637; PubMed Central PMCID: PMCPMC4063122.
  • Zemans RL, Jacobson S, Keene J, et al. Multiple biomarkers predict disease severity, progression and mortality in COPD. Respir Res. 2017;18(1):117. Epub 2017/06/15. DOI:10.1186/s12931-017-0597-7 PubMed PMID: 28610627; PubMed Central PMCID: PMCPMC5470282.
  • Leuzzi G, Galeone C, Taverna F, et al. C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2017;26(143):160070. Epub 2017/02/02. DOI:10.1183/16000617.0070-2016
  • Mannino DM, Tal-Singer R, Lomas DA, et al. Plasma fibrinogen as a biomarker for mortality and hospitalized exacerbations in people with COPD. Chron Obstr Pulm Dis. 2015;2(1):23–34. Epub 2015/02/17. DOI:10.15326/jcopdf.2.1.2014.0138 PubMed PMID: 25685850; PubMed Central PMCID: PMCPMC4326107.
  • Undas A, Jankowski M, Kaczmarek P, et al. Thrombin generation in chronic obstructive pulmonary disease: dependence on plasma factor composition. Thrombosis Res. 2011;128(4):e24-8–e28. Epub 2011/06/01. PubMed PMID: 21624643; PubMed Central PMCID: PMCPMC3183323. DOI:10.1016/j.thromres.2011.05.004
  • Hu G, Wu Y, Zhou Y, et al. Prognostic role of D-dimer for in-hospital and 1-year mortality in exacerbations of COPD. Int J Chron Obstructive Pulm Dis. 2016;11:2729–2736. Epub 2016/11/16. PubMed PMID: 27843309; PubMed Central PMCID: PMCPMC5098517. DOI:10.2147/COPD.S112882
  • Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD audit. Eur Respir J. 2016;47(1):113–121. Epub 2015/10/24. DOI:10.1183/13993003.01391-2014
  • Morasert T, Jantarapootirat M, Phinyo P, et al. Prognostic indicators for in-hospital mortality in COPD with acute exacerbation in Thailand: a retrospective cohort study. BMJ Open Resp Res. 2020;7(1):e000488. Epub 2020/05/30. PubMed PMID: 32467292; PubMed Central PMCID: PMCPMC7259855. DOI:10.1136/bmjresp-2019-000488
  • Moll M, Qiao D, Regan EA, et al. Machine learning and prediction of all-cause mortality in COPD. Chest. 2020;158(3):952–964. Epub 2020/05/01. PubMed PMID: 32353417; PubMed Central PMCID: PMCPMC7478228. DOI:10.1016/j.chest.2020.02.079
  • Horodinschi RN, Bratu OG, Dediu GN, et al. Heart failure and chronic obstructive pulmonary disease: a review. Acta Cardiol. 2020;75(2):97–104. Epub 2019/01/17. DOI:10.1080/00015385.2018.1559485
  • Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–969. Epub 2008/06/27. doi:10.1183/09031936.00012408.
  • Cavaillès A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22(130):454–475. Epub 2013/12/03. DOI:10.1183/09059180.00008612
  • Kostikas K, Clemens A, Patalano F. Prediction and prevention of exacerbations and mortality in patients with COPD. Expert Rev Respir Med. 2016;10(7):739–753. Epub 2016/05/03. DOI:10.1080/17476348.2016.1185371
  • Ashitani J, Mukae H, Arimura Y, et al. Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med. 2002;41(3):181–185. Epub 2002/04/04. DOI:10.2169/internalmedicine.41.181
  • Di Minno MN, Dentali F, Lupoli R, et al. Mild antithrombin deficiency and risk of recurrent venous thromboembolism: a prospective cohort study. Circulation. 2014;129(4):497–503. Epub 2013/10/23. DOI:10.1161/circulationaha.113.003756
  • Sokol J, Timp JF, Cessie S, et al. Mild antithrombin deficiency and risk of recurrent venous thromboembolism: results from the MEGA follow-up study. J Thromb Haemost. 2018;16(4):680–688. Epub 2018/01/30. DOI:10.1111/jth.13960
  • Erelel M, Cuhadaroğlu C, Ece T, et al. The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respir Med. 2002;96(7):515–518. Epub 2002/08/27. DOI:10.1053/rmed.2002.1313
  • Aleva FE, Voets L, Simons SO, et al. Prevalence and localization of pulmonary embolism in unexplained acute exacerbations of COPD: a systematic review and Meta-analysis. Chest. 2017;151(3):544–554. Epub 2016/08/16. DOI:10.1016/j.chest.2016.07.034